- Leukemia (AML): Bristol-Myers Squibb Onureg was approved by EU
- Diet can change intestinal and breast flora and affects breast cancer risk
- WHO: Delta variant will become the world main popular variant virus strain
- Clinical application of interleukin in tumor immunotherapy
- Red meats: DNA damage and colorectal cancer-related gene mutations
- Why reversing intravenous thrombolysis after DOAC is not recommended?
Cure early lung cancer! Imfinzi demonstrates unprecedented survival benefits: treatment of unresectable stage III lung cancer, with a 5-year survival rate of 43%!
Imfinzi treats unresectable stage III lung cancer with 43% 5-year survival rate. AstraZeneca recently announced the latest results of its Phase 3 PACIFIC study.
The data showed that in patients with unresectable, stage III non-small cell lung cancer (NSCLC) who did not develop disease progression after concurrent radiotherapy, the PD-L1 immunosuppressant Imfinzi (Infinzi, common name: durvalumab, degree) was followed up for 5 years. Valliumab) showed sustained, clinically significant overall survival (OS) and progression-free survival (PFS) benefits, 33% of patients had no disease progression after 5 years, and 43% of patients Still alive after 5 years. These data represent the longest survival data reported in immunotherapy for stage III lung cancer.
Lung cancer is the leading cause of cancer deaths, accounting for about one-fifth of all cancer deaths. 80-85% of lung cancer patients are non-small cell lung cancer (NSCLC). A quarter of NSCLC patients are diagnosed in stage III, and most of the tumors are unresectable (cannot be removed by surgery). The purpose of treatment at this stage is to cure. The previous standard treatment was chemotherapy and radiotherapy (CRT), and then active Monitor the progress of the disease, but the prognosis is not ideal, and the long-term survival rate is very low.
According to the results of the PACIFIC study, Imfinzi has been approved in many countries and regions around the world (including the United States, China, Japan, and Europe) for the treatment of patients with unresectable stage III NSCLC who have not progressed after receiving concurrent chemoradiation (CRT) . Imfinzi is the first new treatment available for these patients in decades. Since its first approval in February 2018, more than 80,000 patients worldwide have received Imfinzi treatment.
The latest postmortem analysis showed that after CRT, the 5-year survival rate among Imfinzi-treated patients was estimated to be 42.9%, compared with 33.4% in the placebo group. The median OS was 47.5 months in the Imfinzi group and 29.1 months in the placebo group. After the longest course of treatment for one year, 33.1% of the patients in the Imfinzi group had no disease progression 5 years after enrollment in the study, compared with 19% in the placebo group. These results are based on the main PFS and OS analyses published in the New England Journal of Medicine in 2017 and 2018. These analyses show that Imfinzi has a sustained and significant benefit for these primary endpoints.
David Spigel, an investigator of the PACIFIC trial and chief scientific officer of the Sarah Cannon Institute, said: “This trial has once again created a new precedent for the treatment of unresectable stage III non-small cell lung cancer. Historically, only 15-30% of patients Survived for 5 years, but these results show that with Imfinzi treatment for one year, an estimated 43% of patients are still alive after 5 years, and three-quarters of them have no disease progression during this time. This is here A major achievement made at the 5-year milestone in the stage of the disease for the purpose of curing.”
Dave Fredrickson, Executive Vice President of AstraZeneca’s Oncology Business Unit, said: “For cancer patients and their families, the 5-year survival period is a clinically significant and emotionally significant milestone. It is seen that most patients have 4 years of treatment after completing 1 year of treatment. No progress in years is incredible. These results are the first of its kind for stage III unresectable lung cancer and reinforce the long-term benefits of Imfinzi as an established standard regimen in this curative stage of the disease. “
Stage III (locally advanced) NSCLC is usually divided into 3 subtypes (IIIa, IIIb, IIIc), which are defined by the degree of local spread of the tumor and the possibility of surgery. Stage III is different from stage IV, the latter is that the cancer has spread (metastasis) to distant organs, and the current treatment for most stage III patients is to cure. It is estimated that stage III NSCLC accounts for about a quarter of the incidence of NSCLC. Most of the patients with stage III NSCLC are diagnosed with unresectable tumors. The previous standard treatment was chemotherapy and radiotherapy (CRT), and then active monitoring was performed to monitor the progress of the disease. However, the prognosis of this disease is not ideal, and the long-term survival rate is also very low.
Imfinzi is the first tumor immunotherapy approved for the purpose of curing stage III NSCLC patients after chemoradiotherapy (CRT). Imfinzi is a PD-L1 immunotherapy that targets programmed cell death factor ligand 1 (PD-L1), blocks the interaction of PD-L1 with PD-1 and CD80, and releases the immune evasion strategy against tumors. Inhibition of immune response.
Currently, AstraZeneca is conducting multiple registration trials, focusing on evaluating Imfinzi for the treatment of early stage lung cancer, including potential cures (PACIFIC-2, -4, -5, MERMAID-1, -2, AEGEAN, ADJUVANT BR.31, ADRIATIC and other phase 3 trials). In addition, the company is also conducting two phase II platform trials in the phase III unresectable phase (COAST) and neoadjuvant early treatment phase (NeoCOAST) to test Imfinzi’s new combination therapy.
Imfinzi treats unresectable stage III lung cancer with 43% 5-year survival rate
(source:internet, reference only)